The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Scott Henry - ROTH Capital - Analyst
: Thank you, and good afternoon. I did have a couple of questions. First, with regards to the cancellations, can you talk a little bit about who is
canceling? Are these smaller biotech companies? Are these larger companies? Is it earlier-stage work or later-stage work? Any color that you can
provide would be helpful. Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
DECEMBER 13, 2022 / 9:30PM, CSBR.OQ - Q2 2023 Champions Oncology Inc Earnings Call
Question: Scott Henry - ROTH Capital - Analyst
: Okay. Shifting gears, the revenue guidance of 10% to 15%, I mean, there's only six months left in the year, so that range looks a little wider given
that half of the years through. Do you feel comfortable that you're going to be at one end of that range or are you targeting the middle? And as
well (multiple speakers) talk about the [sales] between Q3 and Q4?
Question: Scott Henry - ROTH Capital - Analyst
: The last part was as well, if you could just talk about the mix between Q3 and Q4? Thank you.
Question: Scott Henry - ROTH Capital - Analyst
: Okay. So should I assume that one would expect Q4 to be stronger than Q3?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
DECEMBER 13, 2022 / 9:30PM, CSBR.OQ - Q2 2023 Champions Oncology Inc Earnings Call
Question: Scott Henry - ROTH Capital - Analyst
: Okay. And I guess the final question, I completely understand the environment cutting noncore business expenses, but I'm curious why the discovery
the target business, you still seem pretty bullish on that category and as well, if maybe if you could just talk about when do you monetize that
discovery target processing? Are you just trying to get through preclinical and then out-license, or do you ever anticipate taking it beyond preclinical?
Just trying to get a sense of how much that business cost and what the timeline to expense recovery is there?
Question: Scott Henry - ROTH Capital - Analyst
: Okay, great. Thank you for taking the questions.
| 
